Recent Finacing
Recent Raise
AcureX Therapeutics develops small‑molecule drugs that reactivate mitophagy by correcting Miro1 signaling, holds exclusive licensed IP, uses Miro1 as a biomarker, and advances Parkinson’s candidates toward human trials.
Focus Areas
Recent Investors
Funding round
Investor
See the team members at AcureX Therapeutics.
